2023
Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P, Robert M, Zhang X. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Archives Of Pathology & Laboratory Medicine 2023, 148: 359-370. PMID: 37327187, DOI: 10.5858/arpa.2022-0537-ra.Peer-Reviewed Original ResearchConceptsDiagnosis of cholangiocarcinomaImmune checkpoint inhibitorsAdvanced tumor stageHeterogeneous tumor groupTumor growth patternEra of precision medicineTherapeutic decision-makingEvaluation of cholangiocarcinomaExtrahepatic biliary treeGenetic testing methodologiesSite of originCheckpoint inhibitorsTumor inaccessibilityMetastatic adenocarcinomaPeriductal infiltrationTumor stageIntraductal tumorClinical presentationDifferentiate cholangiocarcinomaImmunohistochemical profileTumor groupExtrahepatic cholangiocarcinomaTargeted therapyPathological diagnosisIntrahepatic cholangiocarcinoma
2022
The Role of Surgery in Managing Primary and Metastatic Colorectal Cancer
Straker R, Witmer H, Deschner B, Shibata D, Turaga K, Mahmoud N. The Role of Surgery in Managing Primary and Metastatic Colorectal Cancer. 2022, 407-419. DOI: 10.1007/978-3-030-93084-4_38.Peer-Reviewed Original ResearchMetastatic colorectal cancerColorectal cancerPrognostic implicationsLymph nodesDetection of regional lymph node metastasesArea of active ongoing researchManagement of metastatic colorectal cancerRegional lymph node metastasisManagement of peritoneal metastasesAnalysis of tumor specimensHepatic CRC metastasesHyperthermic intraperitoneal chemotherapyHarvested lymph nodesLymph node evaluationLymph node metastasisEra of precision medicineCytoreductive surgeryIntraperitoneal chemotherapyPeritoneal metastasisSurgical resectionAdjuvant therapyTumor specimensSurvival benefitNode metastasisSurgical management
2017
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar R, Chénard-Poirier M, Collins D, Yap T. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers In Medicine 2017, 4: 39. PMID: 28443282, PMCID: PMC5385461, DOI: 10.3389/fmed.2017.00039.Peer-Reviewed Educational MaterialsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerClinical outcome of advanced non-small cell lung cancerOutcomes of advanced non-small cell lung cancerManagement of advanced non-small cell lung cancerLung cancerPrecision medicineEra of precision medicineClinical trial testingImpact of precision medicineDriver aberrationsClinical outcomesNon-smallAntitumor therapyRegulatory approvalMultiple deficienciesCancerHypothesis-testing studiesDiseaseComplex diseasesMedicineTherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply